ViroGates (DB:EP2) - Stock Price, News & Analysis

EP2 Stock Overview

An in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. More details

EP2 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (€119M)

+ 1 more risk

ViroGates A/S Competitors

Geratherm Medical

XTRA:GME

€15.0m

aap Implantate

XTRA:AAQ1

€22.4m

Audientes

DB:AUG

€6.9m

NanoRepro

XTRA:NN6

€19.6m

Price History & Performance

Summary of all time highs, changes and price drops for ViroGates
Historical stock prices
Current Share Price	DKK 2.10
52 Week High	DKK 3.11
52 Week Low	DKK 0.78
Beta	0.78
11 Month Change	155.47%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	150.60%

Recent updates

Shareholder Returns

	EP2	DE Medical Equipment	DE Market
7D	52.2%	-1.0%	-0.02%
1Y	n/a	-7.3%	8.2%

Return vs Industry: Insufficient data to determine how EP2 performed against the German Medical Equipment industry.

Return vs Market: Insufficient data to determine how EP2 performed against the German Market.

Price Volatility

Is EP2's price volatile compared to industry and market?
EP2 volatility
EP2 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stable Share Price: EP2's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine EP2's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	10	Jakob Knudsen	www.virogates.com

ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital emergency services to support the clinical decision on hospitalization or discharge of acute patients and to identify high-risk sepsis patients at an early stage, as well as used for the prognosis of lifestyle-related diseases, such as cardiovascular disease, type 2 diabetes, and cancer; and for the assessment of longevity and biological age in a non-hospital setting. The company’ products icludes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging that will allow clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression and outcome; and suPARnostic POC+, a point-of-care finger prick test that detects the level of suPAR in the blood.

ViroGates A/S Fundamentals Summary

How do ViroGates's earnings and revenue compare to its market cap?
EP2 fundamental statistics
Market cap	€15.97m
Earnings (TTM)	-€1.77m
Revenue (TTM)	€971.88k

16.4x

P/S Ratio

-9.0x

P/E Ratio

Is EP2 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EP2 income statement (TTM)
Revenue	DKK 7.25m
Cost of Revenue	DKK 1.80m
Gross Profit	DKK 5.45m
Other Expenses	DKK 18.69m
Earnings	-DKK 13.23m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.71
Gross Margin	75.22%
Net Profit Margin	-182.57%
Debt/Equity Ratio	74.8%

How did EP2 perform over the long term?

See historical performance and comparison

ViroGates DB:EP2 Stock Report